Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

97
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
97
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94
Scale-Up Processes01:14

Scale-Up Processes

105
The scale-up of microbial fermentation processes is essential in industrial biotechnology, allowing the transition from laboratory-scale experiments to commercial-scale production while aiming to maintain product yield and quality. This process requires meticulous adjustment of equipment design, process parameters, and contamination control strategies to accommodate increasing culture volumes.At the laboratory scale, cultures are typically maintained in 1 to 10-liter glass or autoclavable...
105
Vaccine Production01:23

Vaccine Production

144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
DNA Isolation01:24

DNA Isolation

35.3K
DNA isolation protocols can be fast and straightforward or complex and time-consuming depending on the type and quality of DNA required for further processing. For example, plasmid DNA extraction is a bit more complicated than genomic DNA extraction because of the need for an appropriate lysis method to separate plasmid DNA from gDNA during isolation. However, for specific applications, such as long-range DNA sequencing that require a good yield of high- quality DNA samples, we need to follow...
35.3K
DNA Bacteriophages01:26

DNA Bacteriophages

1.6K
Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Producing Plasmid DNA Template for Clinical Grade RNA Vaccine Manufacture.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord.

Pharmaceutics·2023
Same author

Automated, scaled, transposon-based production of CAR T cells.

Journal for immunotherapy of cancer·2022
Same author

Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Capillary Gel Electrophoresis (CGE) for Quality Control of Plasmid DNA in Gene Therapy: Quality Control of 20 Years Stored GMP-Grade Plasmid DNA.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Correction to: Recombinant expression of Barnase in Escherichia coli and its application in plasmid purifcation.

Microbial cell factories·2021
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K

Pharmaceutical grade large-scale plasmid DNA manufacturing process.

Marco Schmeer1, Martin Schleef

  • 1PlasmidFactory GmbH & Co. KG, Meisenstr. 96, D-33607, Bielefeld, Germany.

Methods in Molecular Biology (Clifton, N.J.)
|April 10, 2014
PubMed
Summary
This summary is machine-generated.

Quality standards for pharmaceutical plasmid DNA vary based on application. Direct gene therapy requires Good Manufacturing Practice (GMP) grade, while plasmid DNA for viral vector production may not need GMP. Upscaling plasmid production is also discussed.

More Related Videos

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks
07:50

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks

Published on: November 25, 2015

14.1K
Generation of Plasmid Vectors Expressing FLAG-tagged Proteins Under the Regulation of Human Elongation Factor-1α Promoter Using Gibson Assembly
10:18

Generation of Plasmid Vectors Expressing FLAG-tagged Proteins Under the Regulation of Human Elongation Factor-1α Promoter Using Gibson Assembly

Published on: February 9, 2015

37.2K

Related Experiment Videos

Last Updated: May 1, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K
Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks
07:50

Plasmid-derived DNA Strand Displacement Gates for Implementing Chemical Reaction Networks

Published on: November 25, 2015

14.1K
Generation of Plasmid Vectors Expressing FLAG-tagged Proteins Under the Regulation of Human Elongation Factor-1α Promoter Using Gibson Assembly
10:18

Generation of Plasmid Vectors Expressing FLAG-tagged Proteins Under the Regulation of Human Elongation Factor-1α Promoter Using Gibson Assembly

Published on: February 9, 2015

37.2K

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Molecular Biology

Background:

  • Plasmid DNA is crucial for pharmaceutical applications, including gene therapy and viral vector production.
  • Regulatory requirements for plasmid DNA quality differ based on its intended use in human treatments.
  • Current production scales range from milligrams in research to grams for industrial applications.

Purpose of the Study:

  • To delineate the quality standards for plasmid DNA in pharmaceutical applications.
  • To differentiate regulatory requirements for direct gene transfer versus viral vector production.
  • To address the challenges and strategies for up-scaling plasmid DNA production.

Main Methods:

  • Review of regulatory guidelines for pharmaceutical-grade plasmid DNA.
  • Comparative analysis of quality requirements for different plasmid DNA applications.
  • Examination of process development for large-scale plasmid DNA manufacturing.

Main Results:

  • Good Manufacturing Practice (GMP) is mandatory for plasmid DNA used in direct human gene transfer.
  • Plasmid DNA for viral vector (e.g., AAV) production may not require GMP, easing manufacturing constraints.
  • Successful up-scaling from laboratory to industrial production levels is feasible.

Conclusions:

  • Plasmid DNA quality control must be tailored to its specific pharmaceutical application.
  • Regulatory flexibility exists for plasmid DNA used in indirect therapeutic approaches like viral vectors.
  • Process optimization is key to achieving efficient and scalable plasmid DNA manufacturing.